Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 26 to 35 of 35

TitleReference numberPublishedLast updated
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxaneTA458
Everolimus with exemestane for treating advanced breast cancer after endocrine therapyTA421
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimensTA423
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancerTA424
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancerTA263
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2TA257
Fulvestrant for the treatment of locally advanced or metastatic breast cancerTA239
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancerTA214
Gemcitabine for the treatment of metastatic breast cancerTA116
Guidance on the use of trastuzumab for the treatment of advanced breast cancerTA34

Results per page

  1. 10
  2. 25
  3. 50
  4. All